- The manufacturing facility in Pune will double Cytiva’s manufacturing capacity in India and the Experience Center will provide critical training programs to accelerate the development of novel therapeutics.
- According to Cytiva’s 2023 Global Biopharma Resilience Index, the manufacturing of biologics in India is likely to increase over the next three years.
Cytiva’s manufacturing facility in Pune, India
As India works to become a biologics manufacturing hub, global life sciences leader Cytiva is expanding with the opening of a 33 000 ft2 manufacturing facility in Pune. The new facility will manufacture Cytiva’s bioprocessing equipment including tangential flow, virus filtration, and inactivation systems.
The facility will also be home to the Cytiva Experience Center which will provide immersive training programs for upstream and downstream technologies as well as digital and automation software. Additionally, customers will have greater access to thought leadership events and to demonstrations of Cytiva’s market-leading products, such as ÄKTA, Allegro, iCELLis and Sepax.
Rajan Sankaran, Commercial General Manager, India, Cytiva, says, “Fortifying our manufacturing footprint in India is critical to Cytiva’s operations in Asia-Pacific and long-term growth strategy. We must also play a key role in developing and nurturing the talent needed to meet the demand for biologic medicines. Our Cytiva Experience Center will provide the ongoing learning and development needed to accelerate the development of novel therapeutics and help India deliver on its Aatmanirbhar Bharat vision and mission.”
Inside Cytiva Experience Center
The facility helps advance the development of new drugs.
Located at Hinjawadi Rajiv Gandhi Infotech Park, this new facility complements Cytiva’s existing facilities in Bengaluru which include a Fast Trak Center, and a center for research and development across bioprocess, discovery, medical, and genomic medicine businesses.
According to Cytiva’s 2023 Global Biopharma Resilience Index, 65% of biopharma executives in India say that the manufacturing of biologics in their country is likely to dramatically increase over the next three years. This is 15% higher than the global average, and in line with India’s National Biopharma Mission to make India a hub for the development of novel and affordable vaccines and biologics to address the population’s health concerns.
Additionally, 46% of biopharma executives in India say that they are focusing on onshoring drug manufacturing or increasing domestic sourcing over the next 12 months to boost supply chain resilience. However, 20% of executives say that access to new equipment has become worse over the last two years, indicating a need to improve local access to equipment so that Indian companies can deliver affordable life-changing therapeutics domestically and to the region.
Interested in visiting our Cytiva Experience Centre? Please contact us here
Read the full 2023 Global Biopharma Resilience Index here.
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 16 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers.
Learn more at cytiva.com
ӒKTA, Allegro, iCELLis, Fast Trak and Sepax are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva